Evonik has reported 1% organic sales growth to EUR3.2bn (US$4bn) and EBITDA better than previous quarters at EUR501m.
For the first nine months of 2014, Evonik posted 2% organic sales growth to around EUR9.7bn and adjusted EBITDA at EUR1.4bn, but below the good prior-period, level due to what the company terms “prices.”
“Evonik did well in an increasingly difficult economic environment,” said Evonik chairman, Klaus Engel. “There has been a clear upward trend in operating earnings this year and in the third quarter they were only slightly below the prior-period level.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“Demand for our products was good despite slower global growth.
